Income statement
AUD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 213M | 162M | 125M | 93M | 68M |
| Gross Profit | 213M | 161M | 92M | 93M | 47M |
| Operating Income | 158M | 115M | 86M | 65M | 44M |
| EBITDA | 165M | 121M | 92M | 70M | 50M |
| Net Income | 115M | 83M | 61M | 44M | 31M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$118.13
-0.82% today
1Y Change
-39.39%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pro Medicus Limited (PMCUF) is a Healthcare stock with a market cap of $14.22B and listed on OTC. The stock last traded around $118.13 and down 39.4% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +31.8%, EPS growth of +39.2%, a dividend yield of 0.5%. What stands out right now is revenue +31.8%, EPS +39.2%, free cash flow +38.1% with operating margin 74.2% and ROIC 25.9%. The dividend is present but secondary, with a yield around 0.5%. Valuation already assumes a fairly strong business story at P/E 60.6 and price/sales 59.1. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines PMCUF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMCUF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PMCUF Max Drawdown
-64.88%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PMCUF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$67.9M
-27.4% YoY
FY Net Income
$30.9M
-30.6% YoY
Free Cash Flow
$31.3M
-41.1% YoY
Revenue Growth
+31.8%
EPS Growth
+39.2%
Gross Margin
78.4%
Net Margin
97.6%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 213M | 162M | 125M | 93M | 68M |
| Gross Profit | 213M | 161M | 92M | 93M | 47M |
| Operating Income | 158M | 115M | 86M | 65M | 44M |
| EBITDA | 165M | 121M | 92M | 70M | 50M |
| Net Income | 115M | 83M | 61M | 44M | 31M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 175M | 60M | 91M | 64M | 42M |
| Total Assets | 339M | 257M | 202M | 157M | 126M |
| Total Liabilities | 82M | 70M | 63M | 55M | 44M |
| Shareholder Equity | 257M | 188M | 139M | 102M | 82M |
| Total Debt | 2M | 2M | 2M | 2M | 3M |
| Net Debt | -172M | -58M | -89M | -61M | -39M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
39M
-37.3% YoY
Capital Expenditures
8M
+14.7% YoY
Free Cash Flow
31M
-41.1% YoY
Key ratios
Gross Margin
78.4%
Operating Margin
74.2%
Net Margin
97.6%
ROE
72.7%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.